VectivBio Holding AG

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the development of treatments for severe rare conditions with significant unmet medical need. Its product pipeline include Apraglutide and CoMet. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population Initial readout of 4-week intestinal energy absorption data expected in 1H22

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure

Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of apraglutide in short bowel syndrome and graft versus host disease, and expansion of its rare disease product portfolio

VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of the first paragraph, the figure of the additional ordinary shares should be 1,125,000, not 1,250,000. The corrected release follows:

CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the closing of its initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters' option to purchase an additional 1,250,000 ordinary shares, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $146.6 million. Vectiv's ordinary shares began trading on the Nasdaq Global Market under the ticker symbol “VECT” on April 9, 2021. All of the ordinary shares were offered by Vectiv.

VectivBio Announces Closing of $146.6 Million Initial Public Offering

CM Life Sciences III - Unit

Five Star Bancorp

Renaissance IPO ETF

Renaissance International IPO ETF

Reneo Pharmaceuticals

Splash Beverage Group

Uber

Zoom Video

Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.

US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today appeared first on InvestorPlace.

Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today

VectivBio Holding and Reneo Pharmaceuticals are making their market debuts on Nasdaq.

Two Biotechs Are Set to Start Trading Today

BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting discounts and commissions.

News for VectivBio Holding AG Stock (VECT)